The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2022 | Methods used to assess MRD status in multiple myeloma
Francesco Maura, MD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, discusses different methods of assessing measurable residual disease (MRD) status in patients with multiple myeloma (MM). These include the use of flow cytometry or next-generation sequencing (NGS) on bone marrow aspirate, imaging, and liquid biopsy. Dr Maura suggests that MRD is a useful dynamic biomarker for response to treatment, but highlights the importance of further identifying the best strategies to use in clinical practice. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
